Published in Sci Transl Med on October 20, 2010
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature (2011) 5.78
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer (2012) 4.97
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 3.47
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood (2008) 3.30
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet (2009) 3.10
Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol (2005) 2.94
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med (2012) 2.86
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell (2008) 2.80
TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J (2013) 2.70
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 2.69
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res (2010) 2.69
Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature (2012) 2.64
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet (2013) 2.38
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med (2012) 2.19
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell (2010) 2.09
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest (2010) 1.93
Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med (2009) 1.89
Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia. Nat Med (2013) 1.89
TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell (2011) 1.87
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev (2010) 1.82
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov (2013) 1.81
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A (2010) 1.81
The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem (2012) 1.79
Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. Blood (2009) 1.78
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell (2007) 1.74
Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med (2013) 1.71
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med (2013) 1.71
Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology (2003) 1.69
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood (2014) 1.68
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med (2012) 1.65
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood (2008) 1.64
Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell (2012) 1.62
The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol (2005) 1.45
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest (2009) 1.44
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood (2010) 1.42
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood (2013) 1.41
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood (2013) 1.37
Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med (2013) 1.36
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood (2013) 1.33
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica (2013) 1.27
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Cancer Discov (2014) 1.25
A common genetic mechanism in malignant bone marrow diseases. N Engl J Med (2009) 1.23
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol (2006) 1.16
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med (2015) 1.15
Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. J Clin Invest (2013) 1.12
A progenitor cell origin of myeloid malignancies. Proc Natl Acad Sci U S A (2009) 1.12
JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol Sci (2012) 1.08
Metabolism and the leukemic stem cell. J Exp Med (2010) 1.08
A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol (2012) 1.07
Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Exp Hematol (2008) 1.05
Potential biomarkers for the diagnosis of stroke. Expert Rev Cardiovasc Ther (2009) 1.03
Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood (2011) 1.02
Molecular biology of myelodysplastic syndromes. Semin Oncol (2011) 1.01
Clinical implications of novel mutations in epigenetic modifiers in AML. Hematol Oncol Clin North Am (2011) 1.01
Isocitrate dehydrogenase mutations in leukemia. J Clin Invest (2013) 1.01
Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood (2006) 1.01
Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res (2014) 0.99
Genetics of myeloproliferative neoplasms. Cancer J (2014) 0.98
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood (2012) 0.96
HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med (2013) 0.94
Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest (2014) 0.94
New pieces of a puzzle: the current biological picture of MPN. Biochim Biophys Acta (2012) 0.93
Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera. Blood (2010) 0.92
Do circulating tumor cells play a role in coagulation and thrombosis? Front Oncol (2012) 0.92
Reperfusion seizures: a manifestation of cerebral reperfusion injury after administration of recombinant tissue plasminogen activator for acute ischemic stroke. J Stroke Cerebrovasc Dis (2007) 0.92
The interface between stroke and infectious disease: infectious diseases leading to stroke and infections complicating stroke. Curr Neurol Neurosci Rep (2009) 0.92
ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. Haematologica (2010) 0.91
How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia? Hematology Am Soc Hematol Educ Program (2012) 0.90
Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. Am J Hematol (2010) 0.88
HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. J Clin Invest (2014) 0.88
Normal IQ in a 55-year-old with newly diagnosed rhombencephalosynapsis. Arch Clin Neuropsychol (2005) 0.88
Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. Curr Opin Oncol (2007) 0.87
Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leuk Res (2012) 0.86
Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematol Oncol Clin North Am (2012) 0.86
LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther (2008) 0.85